Karyopharm TherapeuticsKPTI
13F holders, Q1 2026 (March 31)1holders
1new positions
0sold out
$5.57avg. 13F price*
At the end of Q1 2026, 1 institutions reported holding Karyopharm Therapeutics Inc. (KPTI) in their 13F filings, unchanged from Q3 2025. 1 opened new positions and 0 sold out. The largest holder was Birchview Capital, LP ($468K).
- Company
- Karyopharm Therapeutics Inc.
- CUSIP
- 48576U106
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $468K |
| Exits | 0 | $0 |
All 13F filers, Q3 2025 → Q1 2026: 83,952 shares bought, net +83,952 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| Birchview Capital, LP | 0.27% | New | 83,952 | $468K |
"% of holder's portfolio" is KPTI's weight in each manager's 13F, not the share of Karyopharm Therapeutics Inc. the manager owns.